Filtered By:
Specialty: Neurology
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 360 results found since Jan 2013.

Dose-Related Effects of Statins on Symptomatic Intracerebral Hemorrhage and Outcome After Thrombolysis for Ischemic Stroke Clinical Sciences
Conclusions— We observed an association between increasing dose of statin use and risk of sICH after intravenous thrombolysis. Nevertheless, there was an overall beneficial effect of previous statin use on favorable 3-month outcome.
Source: Stroke - January 27, 2014 Category: Neurology Authors: Scheitz, J. F., Seiffge, D. J., Tutuncu, S., Gensicke, H., Audebert, H. J., Bonati, L. H., Fiebach, J. B., Tranka, C., Lyrer, P. A., Endres, M., Engelter, S. T., Nolte, C. H. Tags: Other Treatment, Thrombolysis Clinical Sciences Source Type: research

Effect of Simvastatin on MMPs and TIMPs in Human Brain Endothelial Cells and Experimental Stroke
Abstract Clinical studies demonstrated favorable effects of statins in stroke beyond lipid-lowering effects. In acute stroke, the disruption of the blood–brain barrier (BBB) is mediated by matrix metalloproteinases (MMPs). A modified MMP metabolism may account for the beneficial effects of statins. Cultured human brain microvascular endothelial cells (BMECs) were pretreated with simvastatin and subjected to oxygen glucose deprivation (OGD). Gene expression and protein secretion of MMP-2 and MMP-9 and the tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 were measured by quantitative real-time polymerase ...
Source: Translational Stroke Research - December 5, 2014 Category: Neurology Source Type: research

Letter by Scheitz et al Regarding Article, “Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient)” Letter to the Editor
Source: Stroke - February 26, 2018 Category: Neurology Authors: Jan F. Scheitz, Kennedy R. Lees, Matthias Endres Tags: Cerebrovascular Disease/Stroke, Intracranial Hemorrhage, Ischemic Stroke, Neuroprotectants Letters to the Editor Source Type: research

Response by Yoshimura et al to Letter Regarding Article, “Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient)” Letter to the Editor
Source: Stroke - February 26, 2018 Category: Neurology Authors: Shinichi Yoshimura, Kazutaka Uchida, Takeshi Morimoto Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke, Neuroprotectants Letters to the Editor Source Type: research

Statin Use and the Risk of Dementia in Patients with Stroke: A Nationwide Population-Based Cohort Study
Background: Patients with stroke have an increased risk of  dementia. Some studies have found that statin use might lower the risk of incident dementia; however, there is still a lack of data from patients with stroke. Therefore, the aim of our study was to investigate the impact of statin use on the risk of dementia in patients with stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - August 6, 2018 Category: Neurology Authors: Mei-Lien Pan, Chien-Chi Hsu, Yi-Min Chen, Hui-Kung Yu, Gwo-Chi Hu Source Type: research

Apolipoproteins B and A1 in Ischemic Stroke Subtypes
Introduction: Elevated serum apolipoprotein B and the apolipoprotein B/A1 ratio have been associated with ischemic stroke and intracranial atherosclerotic disease. We sought to assess the relationship between serum levels of apolipoprotein B, apolipoprotein A1, and the apolipoprotein B/A1 ratio with ischemic stroke subtypes and large artery atherosclerosis location. Materials and Methods: We evaluated serum apolipoprotein B and apolipoprotein A1 levels in consecutive, statin-na ïve, adult ischemic stroke patients admitted to an academic medical center in southern India.
Source: Journal of Stroke and Cerebrovascular Diseases - February 9, 2020 Category: Neurology Authors: Rizwan Kalani, Soumya Krishnamoorthy, D. Deepa, Srinivas Gopala, Dorairaj Prabhakaran, David Tirschwell, P.N. Sylaja Source Type: research

Statin Pretreatment Might Be Associated with Decreased Myocardial Injury After Ischemic Stroke
In this study, we aimed at investigating the association between statin pretreatment and poststroke myocardial injury. Methods: Six hundred seventy-one patients diagnosed as acute ischemic stroke were enrolled. According to the histories of statin pretreatment before stroke, patients were categorized into nonstatin (n  = 474) and statin groups (n = 197), with the latter further divided into low-dosage, standard-dosage, and high-dosage subgroups according the dosages of statins.
Source: Journal of Stroke and Cerebrovascular Diseases - February 20, 2020 Category: Neurology Authors: Ke-Wu Wang, Chao Feng, Yin-Fei Wu, Jing Huang, Wen-Bo Xiao, Shu-Dong Xia Source Type: research

Controversies: Stroke Prevention in Chronic Kidney Disease
Risk of both ischemic and hemorrhagic stroke is increased in the chronic kidney disease (CKD) population, particularly in end-stage kidney disease patients. Uremic factors that contribute to stroke risk include blood pressure variability, vascular calcification, build-up of vascular toxins, chronic inflammation, platelet dysfunction and increased brain microbleeds. This paper discusses the controversial evidence for stroke prevention strategies including blood pressure control, statins, antiplatelet agents, and anticoagulation in the CKD population.
Source: Journal of Stroke and Cerebrovascular Diseases - February 25, 2021 Category: Neurology Authors: Wei Ling Lau Source Type: research

Treatment of Ischemic Stroke by Atorvastatin-Loaded PEGylated Liposome
AbstractThere is insufficient evidence on the effect of nanoparticles, particularly liposomes loaded with a statin, on acute ischemic stroke. We investigated the impact of atorvastatin-loaded PEG (polyethylene glycol) conjugated liposomes (LipoStatin) on the outcomes in rats with cerebral ischemia –reperfusion. PEGylated liposome loaded with atorvastatin was developed as a nanoparticle to specifically accumulate in an ischemic region and release the drug to ameliorate the harmful effects of the stroke. LipoStatin was administered to rats with transient middle cerebral artery occlusion throu gh the tail vein immediately a...
Source: Translational Stroke Research - January 14, 2023 Category: Neurology Source Type: research

Statin Therapy Should Not be Discontinued in Patients With Intracerebral Hemorrhage Controversies in Stroke
Source: Stroke - June 24, 2013 Category: Neurology Authors: Bustamante, A., Montaner, J. Tags: Acute Cerebral Hemorrhage, Cerebral Lacunes, Neuroprotectors, Other Stroke Treatment - Medical Controversies in Stroke Source Type: research

Continued Statin Treatment After Acute Intracranial Hemorrhage: Fighting Fire With Fire Controversies in Stroke
Source: Stroke - June 24, 2013 Category: Neurology Authors: Molina, C. A., Selim, M. H. Tags: Acute Cerebral Hemorrhage, Other Stroke Treatment - Medical Controversies in Stroke Source Type: research

Apolipoprotein E, Statins, and Risk of Intracerebral Hemorrhage Clinical Sciences
Conclusions— Statin use does not seem to attenuate the association of HC with decreased risk for nonlobar ICH. Our data support a gene-by-drug effect for lobar ICH, but larger sample sizes are needed to confirm the association before any clinical change is warranted. Clinical Trial Registration— URL: http://clinicaltrials.gov. Unique identifier: NCT00930280.
Source: Stroke - October 21, 2013 Category: Neurology Authors: Woo, D., Deka, R., Falcone, G. J., Flaherty, M. L., Haverbusch, M., Martini, S. R., Greenberg, S. M., Ayres, A. M., Sauerbeck, L., Kissela, B. M., Kleindorfer, D. O., Moomaw, C. J., Anderson, C. D., Broderick, J. P., Rosand, J., Langefeld, C. D., Woo, J. Tags: Embolic stroke Clinical Sciences Source Type: research

Atorvastatin Treatment and Carotid Plaque Morphology in First-ever Atherosclerotic Transient Ischemic Attack/Stroke: A Case–Control Study
A relationship between echolucency of carotid plaques and the consequent risk of ipsilateral ischemic stroke has been observed. An aggressive lipid-lowering therapy may increase the echogenicity of carotid plaque in patients with elevated low-density lipoprotein cholesterol levels. The aim of this study is to prospectively evaluate the long-term effect of high-dose atorvastatin on carotid plaque morphology in patients with first-ever transient ischemic attack or stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - October 21, 2014 Category: Neurology Authors: Pasquale Marchione, Claudio Vento, Manuela Morreale, Chiara Izzo, Andrea Maugeri, Federica Manuppella, Tommaso Romeo, Patrizia Giacomini Source Type: research

Infratentorial Microbleeds: Another Sign of Microangiopathy in Migraine Brief Reports
Conclusions— Migraine, notably without aura, is associated with infratentorial CMBs at older age. CMBs and infarcts co-occur more often in migraine than in controls. This supports the hypothesis of small-vessel involvement in migraine pathophysiology.
Source: Stroke - June 22, 2015 Category: Neurology Authors: Arkink, E. B., Terwindt, G. M., de Craen, A. J. M., Konishi, J., van der Grond, J., van Buchem, M. A., Ferrari, M. D., Kruit, M. C., on behalf of the PROSPER Study Group Tags: Cerebrovascular disease/stroke, Computerized tomography and Magnetic Resonance Imaging, Risk Factors for Stroke Brief Reports Source Type: research

HMG-CoA Reductase Inhibitor (Statin) Prescribing for Ischemic Stroke Patients at Hospital Discharge (P2.306)
Conclusions: Our observations suggest that neurologists may be more likely to prescribe a statin at the time of discharge for whites in group 3 (diabetics age 40-75 with LDL 70-189 without ASCVD) when compared to their black counterparts. Further research is needed to determine if racial disparities exist in discharge statin prescribing for stroke survivors.Disclosure: Dr. Albright has nothing to disclose. Dr. Vahidy has nothing to disclose. Dr. Sisson has nothing to disclose. Dr. Samai has nothing to disclose. Dr. Schluter has nothing to disclose. Dr. Martin-Schild has received personal compensation for activities with Genentech.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Albright, K., Vahidy, F., Moore, M., Samai, A., Schluter, L., Martin-Schild, S. Tags: Stroke Systems of Care Source Type: research